세계의 심장 바이오 임플란트 기기 시장 예측 : 유형별, 용도별, 최종사용자별, 국가별, 기업별 분석(2024-2032년)

Global Cardiac Bio Implant Devices Market Analysis

The market for the Cardiac Bio Implant Devices will be US$ 69.12 billion by 2032 from US$ 37.13 billion in 2023 with a Compound Annual Growth Rate of 7.15% between 2024 and 2032. Cardiac bioimplant arises from causes-such as the aging population, relatively higher incidences of cardiovascular diseases, developments in biomaterial science and an ever-rising global population with a penchant for procedures that do not require much intrusion.

Cardiac Bio Implant Devices Outlooks

Cardiac bioimplant devices are miniaturized health systems that regulate and cure disease of the heart containers. Such devices include pacemakers, defibrillators, bio-prosthetic heart valves as well as ventricular assist devices (VADs). Pacemakers therefore assist in controlling irregular heartbeats using electrical signals that are capable of controlling the heartbeat. In turn, defibrillators are used to apply electrical shocks to the heart if it identifies medically serious forms of the arrhythmia. Mechanical heart valves are synthetic and replace the natural ones that are either faulty or have a disease, and keep the blood flowing in the right way through the heart VADs assist patients with severe heart failure help by supplementing the pumping function of the heart especially to those awaiting on heart transplants.

These cardiac bio-implant devices improve the quality of life of patients with cardiac issues by filling the gap in heart tissue. It therefore relieves symptoms, enhances the function of the heart, and decreases the probability of fatal occurrences. Pacemakers and defibrillators are used to approach a proper rhythm and avoid such conspicuous issues as stroke or failure of the heart. Bio-prosthetic heart valves enhance the circulation of blood in the body meaning less workload to the heart. VADs offer much-needed support to the patients with end stage heart failure, boosting the patients' survival rates and general well-being while waiting for the heart transplant. New technological development gives a silver lining and better prospects for tens of millions of patients globally.

Driving Forces for Cardiac Bio Implant Devices Market

Aging population worldwide

The global ageing population is one of the main growth stimulants for the cardiac bio implant devices market. Cardiovascular diseases include heart failure, arrhythmias, and valvular heart diseases, and their occurrence raises with age. Patients above 65 years are prone to suffer different heart diseases that need invasive procedures like pacemakers, defibrillators, and even valves. This has ensured that there is an increase in the number of elderly people, and hence the need for these lives supporting inventions hence increasing the market. Also, new innovations in the medical field and better health structures make the delivery of these devices to a crucial demographic of the aging population feasible, thereby boosting its market.

Technological Advancements

The market for Cardiac bio-implant devices is advancing due to the introduction of the latest technology in the medical field. New technologies including leadless pacemakers, MRI compatible devices, and Minimal invasive surgery these have enhanced the safety and performance of these implants and also the comfort of the patients. The portable devices with remote monitoring permits a constant assessment of the conditions of the patients and their timely intervention to prevent hospitalizations and worsened results. Also, technological improvements in the synthesis of the biomaterials and tissue engineering helped in improving the strength and performance of existing bio-prosthetic heart valves hence extending their use. These are the technological advancements that are acting as the driving force for the market as it provides better treatment facilities and has expanded the usage of cardiac bio-implants.

Rising Incidence of Cardiovascular Diseases

Rising incidence of cardiovascular diseases is a key factor that will foster the growth of the overall market for cardiac bio implant devices. Most people consume unhealthy foods, hardly exercise, lead a sedentary life, are overweight and stressed which are leading them to increased cases of heart diseases globally. As a large number of the patients are diagnosed with diseases like heart failure, arrhythmia, or CAD, the need for troubled solutions, cardiac bio-implants, increases as well. Suppliers also find governments and healthcare sectors promoting awareness campaigns and early diagnosis programs so as to increase the chances of identifying patients with the cardiac diseases, contributing to the enhanced requirement for the implantable devices to manage the diseases.

Favourable Reimbursement Policies

The reimbursement policies in particular and the insurance coverage of the cardiac bio-implant procedures are key factors that have huge impacts on the growth of the market. Different developed countries have health insurance schemes and government healthcare programs that cater for a number of costs pertaining to cardiac implants. It assists in alleviating the costs of treatment and extends the possibility of great-quality cardiac treatment to more people. Also, prices have been influenced by the shift in health care reforms and outcomes-based care which include the use of high quality cardiac implant devices. It is these employment policies and financial incentive that contributes to the market by ensuring these invaluable pieces of equipment's are easily within reach.

Asia Pacific Cardiac Bio Implant Devices Market

With the increased rate of cardiovascular disease, increasing population, and higher health care expenses, the Asia Pacific cardiac bio implant devices market is progressing at a higher rate. Administrations of countries such as China, India, and Japan are major players in opening up the market due to the advancement of healthcare facilities and increased awareness of cardiac diseases. Some of these drivers include; technological progress and development such as minimally invasive surgeries and improved bio-prosthetic heart valves. More so, the availably of the devices is boosting through friendly government policies and take up of insurance products. This market is further augmented by the rising focus on the early screening and prevention that enhance the sales of pacemakers, defibrillators, and other cardio devices in the region.

Cardiac Bio Implant Devices Company Analysis

The top companies in the Cardiac Bio Implant Device industry are F. Hoffman-La Roche, Eurofins Scientific, Illumina, Inc., Natera, Inc., Abbott Laboratories, Thermo Fisher Scientific, Quest Diagnostics, and Agilent Technologies.

Cardiac Bio Implant Devices Company News

Roche signed a $2.7 billion cash deal in December 2023 to acquire US-based Carmot Therapeutics.

In February 2021, Medtronic introduced the TYRX Absorbable Antibacterial Envelope. This unique, one-time-use envelope has antimicrobial qualities and supports implanted neurostimulators or cardiac implantable electrical devices.

Type- Market breakup in 3 viewpoints:

1. Pacemaker

2. ICDs

3. CRT

Application- Market breakup in 4 viewpoints:

1. Arrhythmias

2. Myocardial Ischemia

3. Acute Myocardial Infarction

4. Heart Failure

End User- Market breakup in 4 viewpoints:

1. Hospitals

2. Ambulatory Surgical Centers

3. Cardiac Catheterization Laboratories

4. Others

Country - Market breakup of 25 Countries:

1. North America

• 1.1 United States
• 1.2 Canada

2. Europe

• 2.1 France
• 2.2 Germany
• 2.3 Italy
• 2.4 Spain
• 2.5 United Kingdom
• 2.6 Belgium
• 2.7 Netherland
• 2.8 Turkey

3. Asia Pacific

• 3.1 China
• 3.2 Japan
• 3.3 India
• 3.4 South Korea
• 3.5 Thailand
• 3.6 Malaysia
• 3.7 Indonesia
• 3.8 Australia
• 3.9 New Zealand

4. Latin America

• 4.1 Brazil
• 4.2 Mexico
• 4.3 Argentina

5. Middle East & Africa

• 5.1 Saudi Arabia
• 5.2 UAE
• 5.3 South Africa

6. Rest of the world

All the key players have been covered from 4 Viewpoints:

• Business Overview
• Product Portfolio
• Recent Development & Strategies
• Revenue Analysis

Key Players Analysis:

1. F. Hoffman-La Roche

2. Eurofins Scientific

3. Illumina, Inc.

4. Natera Inc.

5. Abbott Laboratories

6. Thermo Fisher Scientific

7. Quest Diagnostics

8. Agilent Technologies

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Drivers
• 4.2 Challenges

5. Cardiac Bio Implant Devices Market

6. Market Share

• 6.1 By Type
• 6.2 By Application
• 6.3 By End User
• 6.4 By Countries

7. Type

• 7.1 Pacemaker
• 7.2 ICDs (Implantable Cardioverter Defibrillator)
• 7.3 CRT (Cardiac Resynchronization Therapy)

8. Application

• 8.1 Arrhythmias
• 8.2 Myocardial Ischemia
• 8.3 Acute Myocardial Infarction
• 8.4 Heart Failure

9. End-User

• 9.1 Hospitals
• 9.2 Ambulatory Surgical Centers
• 9.3 Cardiac Catheterization Laboratories
• 9.4 Others

10. Countries

• 10.1 North America
  • 10.1.1 United States
  • 10.1.2 Canada
• 10.2 Europe
  • 10.2.1 France
  • 10.2.2 Germany
  • 10.2.3 Italy
  • 10.2.4 Spain
  • 10.2.5 United Kingdom
  • 10.2.6 Belgium
  • 10.2.7 Netherlands
  • 10.2.8 Switzerland
• 10.3 Asia Pacific
  • 10.3.1 China
  • 10.3.2 Japan
  • 10.3.3 India
  • 10.3.4 Australia
  • 10.3.5 South Korea
  • 10.3.6 Thailand
  • 10.3.7 Malaysia
  • 10.3.8 Indonesia
  • 10.3.9 Philippines
• 10.4 Latin America
  • 10.4.1 Brazil
  • 10.4.2 Mexico
  • 10.4.3 Argentina
• 10.5 MEA
  • 10.5.1 South Africa
  • 10.5.2 Saudi Arabia
  • 10.5.3 Turkey
  • 10.5.4 UAE
• 10.6 Rest of the World

11. Porter's Five Forces Analysis

• 11.1 Bargaining Power of Buyers
• 11.2 Bargaining Power of Suppliers
• 11.3 Degree of Rivalry
• 11.4 Threat of New Entrants
• 11.5 Threat of Substitutes

12. SWOT Analysis

• 12.1 Strength
• 12.2 Weakness
• 12.3 Opportunity
• 12.4 Threat

13. Key Players Analysis

• 13.1 F. Hoffman-La Roche
  • 13.1.1 Overview
  • 13.1.2 Product Portfolio
  • 13.1.3 Recent Development
  • 13.1.4 Revenue Analysis
• 13.2 Eurofins Scientific
  • 13.2.1 Overview
  • 13.2.2 Product Portfolio
  • 13.2.3 Recent Development
  • 13.2.4 Revenue Analysis
• 13.3 Illumina, Inc.
  • 13.3.1 Overview
  • 13.3.2 Product Portfolio
  • 13.3.3 Recent Development
  • 13.3.4 Revenue Analysis
• 13.4 Natera Inc.
  • 13.4.1 Overview
  • 13.4.2 Product Portfolio
  • 13.4.3 Recent Development
  • 13.4.4 Revenue Analysis
• 13.5 Abbott Laboratories
  • 13.5.1 Overview
  • 13.5.2 Product Portfolio
  • 13.5.3 Recent Development
  • 13.5.4 Revenue Analysis
• 13.6 Thermo Fisher Scientific
  • 13.6.1 Overview
  • 13.6.2 Product Portfolio
  • 13.6.3 Recent Development
  • 13.6.4 Revenue Analysis
• 13.7 Quest Diagnostics
  • 13.7.1 Overview
  • 13.7.2 Product Portfolio
  • 13.7.3 Recent Development
  • 13.7.4 Revenue Analysis
• 13.8 Agilent Technologies
  • 13.8.1 Overview
  • 13.8.2 Product Portfolio
  • 13.8.3 Recent Development
  • 13.8.4 Revenue Analysis